Expression and role of MHC class I-related chain in myeloma cells

References

• Trinchieri G. Biology of natural killer cells. Adv Immunol 1989; 47: 187–376
   PubMed Web of Science ®Google Scholar
• Pende D, Cantoni C, Rivera P, et al. Role of NKG2D in tumor cell lysis mediated by human NK cells: cooperation with natural cytotoxicity receptors and capability of recognizing tumors of nonepithelial origin. Eur J Immunol 2001; 31: 1076–86
   PubMed Web of Science ®Google Scholar
• Groh V, Rhinehart R, Secrist H, et al. Broad tumor-associated expression and recognition by tumor-derived gamma delta T cells of MICA and MICB. Proc Natl Acad Sci USA 1999; 96: 6879–84
   PubMed Web of Science ®Google Scholar
• Pende D, Rivera P, Marcenaro S, et al. Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes: analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity. Cancer Res 2002; 62: 6178–86
   PubMed Web of Science ®Google Scholar
• Salih HR, Antropius H, Gieseke F, et al. Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia. Blood 2003; 102: 1389–96
   PubMed Web of Science ®Google Scholar
• Jinushi M, Takehara T, Tatsumi T, et al. Expression and role of MICA and MICB in human hepatocellular carcinomas and their regulation by retinoic acid. Int J Cancer 2003; 104: 354–61
   PubMed Web of Science ®Google Scholar
• Vivier E, Tomasello E, Paul P. Lymphocyte activation via NKG2D: towards a new paradigm in immune recognition?. Curr Opin Immunol 2002; 14: 306–11
   PubMed Web of Science ®Google Scholar
• Bauer S, Groh V, Wu J, et al. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 1999; 285: 727–9
   PubMed Web of Science ®Google Scholar
• Wu J, Song Y, Bakker AB, et al. An activating immunoreceptor complex formed by NKG2D and DAP10. Science 1999; 285: 730–2
   PubMed Web of Science ®Google Scholar
• Groh V, Bahram S, Bauer S, et al. Cell stress-regulated human major histocompatibility complex class I gene expressed in gastrointestinal epithelium. Proc Natl Acad Sci USA 1996; 93: 12445–50
   PubMed Web of Science ®Google Scholar
• Groh V, Rhinehart R, Randolph-Habecker J, et al. Costimulation of CD8 alphabeta T cells by NKG2D via engagement by MIC induced on virus-infected cells. Nat Immunol 2001; 2: 255–60
   PubMed Web of Science ®Google Scholar
• Tieng V, Le Bouguenec C, du Merle L, et al. Binding of Escherichia coli adhesion AfaE to CD55 triggers cell-surface expression of the MHC class I-related molecule MICA. Proc Natl Acad Sci USA 2002; 99: 2977–82
   PubMed Web of Science ®Google Scholar
• Das H, Groh V, Kuijl C, et al. MICA engagement by human Vgamma2Vdelta2 T cells enhances their antigen-dependent effector function. Immunity 2001; 15: 83–93
   PubMed Web of Science ®Google Scholar
• Cunningham D, Powles R, Malpas J, et al. A randomized trial of maintenance interferon following high-dose chemotherapy in multiple myeloma: long-term follow-up results. Br J Haematol 1998; 102: 495–502
   PubMed Web of Science ®Google Scholar
• Ludwig H, Cohen AM, Polliack A, et al. Interferon-alpha for induction and maintenance in multiple myeloma: results of two multicenter randomized trials and summary of other studies. Ann Oncol 1995; 6: 467–76
   PubMed Web of Science ®Google Scholar
• Myeloma Trialists’ Collaborative Group. Interferon as therapy for multiple myeloma: an individual patient data overview of 24 randomized trials and 4012 patients. Br J Haematol 2001; 113: 1020–34
   PubMed Web of Science ®Google Scholar
• Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999; 341: 1565–71
   PubMed Web of Science ®Google Scholar
• Davies FE, Raje N, Hideshima T, et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 2001; 98: 210–16
   PubMed Web of Science ®Google Scholar
• Kunzmann V, Bauer E, Feurle J, et al. Stimulation of gammadelta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma. Blood 2000; 96: 384–92
   PubMed Web of Science ®Google Scholar
• Das H, Wang L, Kamath A, Bukowski JF. Vgamma2Vdelta2 T-cell receptor-mediated recognition of aminobisphosphonates. Blood 2001; 98: 1616–18
   PubMed Web of Science ®Google Scholar
• Alyea E, Weller E, Schlossman R, et al. Outcome after autologous and allogeneic stem cell transplantation for patients with multiple myeloma: impact of graft-versus-myeloma effect. Bone Marrow Transplant 2003; 32: 1145–51
   PubMedGoogle Scholar
• Barlogie B, Shaughnessy J, Tricot G, et al. Treatment of multiple myeloma. Blood 2004; 103: 20–32
   PubMed Web of Science ®Google Scholar
• Lokhorst HM, Wu K, Verdonck LF, et al. The occurrence of graft versus host disease is the major predictive factor for response to donor lymphocyte infusions in multiple myeloma. Blood 2004; 103: 4362–4
   PubMed Web of Science ®Google Scholar
• Frohn C, Hoppner M, Schlenke P, et al. Anti-myeloma activity of natural killer lymphocytes. Br J Haematol 2002; 119: 660–4
   PubMed Web of Science ®Google Scholar
• Garcia-Sanz R, Gonzalez M, Orfao A, et al. Analysis of natural killer-associated antigens in peripheral blood and bone marrow of multiple myeloma patients and prognostic implications. Br J Haematol 1996; 93: 81–8
   PubMed Web of Science ®Google Scholar
• Gonzalez M, San Miguel JF, Gascon A, et al. Increased expression of natural-killer-associated and activation antigens in multiple myeloma. Am J Hematol 1992; 39: 84–9
   PubMed Web of Science ®Google Scholar
• King MA, Radicchi-Mastroianni MA. Natural killer cells and CD56+ T cells in the blood of multiple myeloma patients: analysis by 4-colour flow cytometry. Cytometry 1996; 26: 121–4
   PubMedGoogle Scholar
• Osterborg A, Nilsson B, Bjorkholm M, et al. Natural killer cell activity in monoclonal gammopathies: relation to disease activity. Eur J Haematol 1990; 45: 153–7
   PubMed Web of Science ®Google Scholar
• Bahram S, Bresnahan M, Geraghty DE, Spies T. A second lineage of mammalian major histocompatibility complex class I genes. Proc Natl Acad Sci USA 1994; 91: 6259–63
   PubMed Web of Science ®Google Scholar
• Farag SS, Fehniger TA, Ruggeri L, et al. Natural killer cell receptors: new biology and insights into the graft-versus-leukemia effect. Blood 2002; 100: 1935–47
   PubMed Web of Science ®Google Scholar
• Cosman D, Mullberg J, Sutherland CL, et al. ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. Immunity 2001; 14: 123–33
   PubMed Web of Science ®Google Scholar
• Takahashi R, Shimazaki C, Inaba T, et al. A newly developed bisphosphonate, YM529, is a potent apoptosis inducer of human myeloma cells. Leuk Res 2001; 25: 77–83
   PubMed Web of Science ®Google Scholar
• Carbone E, Neri P, Mesuraca M, et al. HLA class-I, NKG2D and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells. Blood 2005; 105: 251–8
   PubMed Web of Science ®Google Scholar